Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 37261 - 37280 out of 566325 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Australia | (L01FX13) enfortumab vedotin | Padcev 20 mg powder for injection, 1 vial | Powder for I.V. infusion 20 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX13) enfortumab vedotin | Padcev 20 mg powder for injection, 1 vial | Powder for I.V. infusion 20 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX13) enfortumab vedotin | Padcev 30 mg powder for injection, 1 vial | Powder for I.V. infusion 30 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX13) enfortumab vedotin | Padcev 30 mg powder for injection, 1 vial | Powder for I.V. infusion 30 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX13) enfortumab vedotin | Padcev 30 mg powder for injection, 1 vial | Powder for I.V. infusion 30 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX20) tremelimumab | Imjudo 300 mg/15 mL injection, 15 mL vial | Solution concentrate for I.V. infusion 300 mg in 15 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FX20) tremelimumab | Imjudo 300 mg/15 mL injection, 15 mL vial | Solution concentrate for I.V. infusion 300 mg in 15 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FX20) tremelimumab | Imjudo 300 mg/15 mL injection, 15 mL vial | Solution concentrate for I.V. infusion 300 mg in 15 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
Pages
